The Duke Clinical and Translational Science Institute (CTSI) is collaborating with the Duke Department of Emergency Medicine on a study to evaluate the effectiveness of COVID-19 vaccines and the long-term impact of infection among health care personnel.
CTSI’s research site at Duke Kannapolis oversees and manages recruitment and enrollment for the project at Duke, one of 20 sites nationwide for the public health surveillance project dubbed Preventing Emerging Infections Through Vaccine Effectiveness Testing, or PREVENT II. Anyone who works at a Duke Health location and has recently been tested for COVID-19, whether positive or negative for infection, may be eligible to participate.
Duke Emergency Medicine is partnering with the U.S. Centers for Disease Control and Prevention (CDC) and the University of Iowa on the study.
To learn more or to see if you are eligible to be part of the study click here.